Top 20 life sciences deals list highlights 2025’s rebound

PharmaShots has published its “Top 20 Life Sciences Deals of 2025,” a year-end roundup created with DealForma data that ranks the biggest transactions across life sciences. The list points to a deal environment shaped by large M&A, private capital, and late-year strategic moves, with examples including Shionogi’s $2.5 billion Mitsubishi Tanabe Pharma business unit purchase, Blackstone’s close of its $6.3 billion BXLS VI life sciences fund, and other headline transactions highlighted separately by PharmaShots, including CVC Capital Partners’ proposed roughly €10.9 billion acquisition of Recordati and Eli Lilly’s announced acquisition of Centessa. (linkedin.com)

Why it matters: For veterinary professionals, this isn’t animal health news on its face, but it is a useful signal about where healthcare capital is flowing. Broader life sciences dealmaking accelerated in 2025 after a slower start, with Deloitte reporting 193 life sciences M&A transactions totaling $220 billion by the end of November and EY putting total 2025 life sciences M&A at about $240 billion, driven in part by patent-cliff pressure and demand for external innovation. That matters because financing conditions, platform consolidation, and AI-focused partnering in human biopharma often spill over into companion animal diagnostics, therapeutics, and investor expectations for veterinary startups. (deloitte.com)

What to watch: Watch whether 2026 deal activity broadens from mega-deals into more animal health, diagnostics, and tech-enabled care transactions as large funds and strategics keep looking for growth platforms. (deloitte.com)